Navigation Links
Amylin Pharmaceuticals to Present at Goldman Sachs Global Healthcare Conference
Date:6/5/2008

SAN DIEGO, June 5 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will be presenting at the Goldman Sachs Global Healthcare Conference in Dana Point on Wednesday, June 11, 2008 at 1:20 p.m. PT. Daniel M. Bradbury, President and Chief Executive Officer of Amylin Pharmaceuticals, will be providing a corporate overview.

The live presentation will be Web cast, and a recording will be made available following the event. The Web cast and recording will be accessible through Amylin's corporate Web site, located at http://www.amylin.com. To access the live Web cast, please log on to Amylin's site approximately fifteen minutes prior to the presentation to register and download any necessary audio software.

About Amylin Pharmaceuticals

Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California with over 2,000 employees nationwide. Further information on Amylin Pharmaceuticals is available at http://www.amylin.com.


'/>"/>
SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Amylin Pharmaceuticals to Present Promising Data From Diabetes and Obesity Programs at ADA 2008
2. Amylin Pharmaceuticals to Present at Annual Meeting of Stockholders
3. Amylin Pharmaceuticals to Present at FBR Capital Markets Investor Conference
4. Amylin Pharmaceuticals to Present at Baird Growth Stock Conference
5. Amylin Pharmaceuticals to Present at Bank of America Healthcare Conference
6. Amylin Pharmaceuticals Announces Time Change to Previously Announced Presentation at the Morgan Stanley Global Healthcare Unplugged Conference
7. Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare Unplugged Conference
8. Amylin Pharmaceuticals to Webcast First Quarter Results
9. Amylin Pharmaceuticals to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
10. Amylin Pharmaceuticals to Present at Nasdaq 20th Investor Program
11. Xenome Receives a Syndicated US$10 Million Equity Investment from Queensland BioCapital Fund, Amylin Pharmaceuticals and Innovis Investment Partners
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... , May 4, 2016  Bayer today ... oncology compound Stivarga ® (regorafenib) tablets for ... (HCC) has met its primary endpoint of a ... called RESORCE, evaluated the efficacy and safety of ... progressed after treatment with sorafenib. The safety and ...
(Date:5/4/2016)... ... ... PBI-Gordon Corporation is pleased to announce Doug Obermann has been promoted to ... PBI-Gordon in February 1988, after finishing his masters in agronomy from Iowa State University. ... to national product manager, to helping develop, name and launch many of the most ...
(Date:5/3/2016)... Francisco, CA (PRWEB) , ... May 03, 2016 ... ... Morf Playbook™ enterprise talent development, skill-building and compliance training platform on mobile ... training course: Overview of Regulatory Requirements for Medical Devices. The course is ...
(Date:5/3/2016)... ... May 03, 2016 , ... Flagship Biosciences, ... Nancy Gillett to its Board of Directors. Dr. Gillett recently retired from Charles ... Vice President and Chief Scientific Officer. A board-certified veterinary pathologist, Dr. Gillett joined ...
Breaking Biology Technology:
(Date:4/15/2016)...  A new partnership announced today will help ... in a fraction of the time it takes ... life insurance policies to consumers without requiring inconvenient ... Diagnostics, rapid testing (A1C, Cotinine and HIV) and ... weight, pulse, BMI, and activity data) available at ...
(Date:3/31/2016)... -- Genomics firm Nabsys has completed a financial  restructuring under ... M.D., who returned to the company in October 2015. ... including Chief Technology Officer, John Oliver , Ph.D., ... Vice President of Software and Informatics, Michael Kaiser ... Bready served as CEO of Nabsys from 2005-2014 and ...
(Date:3/21/2016)... , March 22, 2016 ... recognition with passcodes for superior security   ... a leading provider of secure digital communications services, today ... biometric technology and offer enterprise customers, particularly those in ... facial recognition and voice authentication within a mobile app, ...
Breaking Biology News(10 mins):